Operates a chain of medical diagnostic centres offering pathology testing, X-ray, Ultrasound, ECG, TMT and ECHO services to individual patients and institutional clients. The most recent operational update is the opening of a new strategic centre at Vardhman Star City Mall in Dwarka, New Delhi, positioned to tap the government-employee population in the Dwarka and Palam belt, with management indicating expected revenue of approximately Rs. 1 crore per annum from that facility. FY26 revenue from operations stood at Rs. 418.58 lacs, down about 6% from Rs. 445.38 lacs in FY25. The cost structure is dominated by materials (40.3% of revenue) and other operating expenses (39.1%), with employee costs at 18.9% and capex at 7.9% of revenue. The audited results for FY26 flagged NPA status with lenders, defaults on loan repayments, and unpaid PF/ESIC/TDS statutory dues since July 2024, with a pre-exceptional loss of Rs. 51.31 lacs offset by a one-time OTS gain of Rs. 61.08 lacs to reach a small reported profit. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Diagnostic services. Small, single-segment diagnostic services provider with stressed finances and elevated statutory liabilities
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 11 | 5 | 5 | 4 | 4 |
| EBITDA (ex other income) | — | — | — | — | — |
| margin % | — | — | — | — | — |
| Owners' profit | — | — | — | — | — |
| EPS, as reported (₹) | 2.15 | (3.61) | 1.43 | 1.43 | 0.07 |
| ROE % · ROCE % | — · 13.7 | — · (4.6) | — · 10.0 | — · 4.8 | — · 0.8 |
| Debt / equity (x) | — | — | — | — | — |
| Cash from operations | 1 | (1) | (0) | 0 | (1) |
| Capex | — | — | — | (0) | (0) |
| ₹ crore | Q2 FY23 | Q4 FY23 | Q2 FY24 | Q4 FY24 | Q2 FY25 | Q4 FY25 | Q2 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2 | 3 | 3 | 2 | 2 | 2 | 2 | 2 |
| Profit before tax | (1) | (1) | (0) | 1 | 0 | 0 | 0 | (0) |
| Net profit | — | — | — | — | — | — | — | — |
| EPS (₹) | (2.25) | (2.25) | (0.20) | 1.63 | 0.35 | 0.61 | 0.45 | 0.15 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| DR. LAL PATH LABS LTD. | 31,794 | 45.7 | 12.51 | 37.0 | 20.1 | 24.8 | 11.8 | 35.0 |
| VIJAYA DIAGNOSTIC CEN LTD | 15,456 | 82.4 | 16.15 | 43.1 | 18.1 | 16.8 | — | 46.4 |
| METROPOLIS HEALTHCARE LTD | 12,088 | 25.0 | 7.93 | 28.9 | 12.5 | 14.4 | 10.5 | 25.8 |
| THYROCARE TECH LTD | 8,797 | 32.3 | 15.01 | 32.1 | 27.8 | 33.2 | 10.9 | 33.9 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 17 Jul 2026 · Compliance Certificate for Depository Operations Q1 FY27 | compliance | minimal | — | — |
| 3 Jun 2026 · Audited Financial Results for the quarter and year ended March 31, 2026 | results | high | — | — |
| 3 Jun 2026 · Audited Financial Results for the half year and year ended March 31, 2206 | results | high | — | — |
| 30 May 2026 · Intimation of Postponement and Rescheduling of Board Meeting scheduled to be held on Today May 30, 2026. | board shareholder meetings | medium | — | — |
| 28 May 2026 · We are pleased to inform that the Company has successfully opened a new strategic Centre at Dwarka New Delhi. | business updates | medium | — | — |
| 27 May 2026 · Dr Lalchandani Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve financial results of the .... | results | low | — | — |
| 4 May 2026 · <b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> .... | compliance | minimal | — | — |
| 30 Apr 2026 · Initial Disclosure - Not Classified as a Large Corporate | compliance | minimal | — | — |
| 22 Apr 2026 · Resignation of Mrs. Saniya Hussain from the position of Company Secretary and Compliance Officer | management changes | medium | — | — |
| 13 Apr 2026 · Reply to the clarification sought by exchange dated April 13, 2026 | compliance | minimal | — | — |
| NEPHROCARE HEALTH SERV L | 7,678 | 79.3 | 6.88 | 30.4 | 6.9 | 8.6 | — | 25.3 |
| KRSNAA DIAGNOSTICS LTD | 1,794 | 18.4 | 1.83 | 9.0 | 10.3 | 8.4 | — | 27.7 |
| SURAKSHA DIAGNOSTIC LTD | 1,693 | 47.2 | 6.95 | 17.2 | 12.9 | 11.5 | — | 36.0 |
| 3B BLACKBIO DX LTD. | 1,217 | 20.3 | 3.67 | 14.3 | 18.1 | 22.5 | (8.9) | 52.6 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 5.3 | 23.2 | 5 of 29 | 86% |
| ROCE | 0.7 | 6.1 | 21 of 29 | 29% |
| Revenue growth | 2.5 | 20.8 | 21 of 25 | 17% |
| Market cap | 7 | 38 | 27 of 30 | 10% |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
